Show simple item record

dc.contributor.authorTerri, Michela
dc.contributor.authorSandoval, Pilar
dc.contributor.authorBontempi, Giulio
dc.contributor.authorMontaldo, Claudia
dc.contributor.authorTomero-Sanz, Henar
dc.contributor.authorde Turris, Valeria
dc.contributor.authorTrionfetti, Flavia
dc.contributor.authorPascual-Antón, Lucía
dc.contributor.authorClares-Pedrero, Irene
dc.contributor.authorBattistelli, Cecilia
dc.contributor.authorValente, Sergio
dc.contributor.authorZwergel, Clemens
dc.contributor.authorMai, Antonello
dc.contributor.authorRosanò, Laura
dc.contributor.authordel Pozo, Miguel Angel 
dc.contributor.authorSánchez-Álvarez, Miguel
dc.contributor.authorCabañas, Carlos
dc.contributor.authorTripodi, Marco
dc.contributor.authorLópez-Cabrera, Manuel
dc.contributor.authorStrippoli, Raffaele 
dc.date.accessioned2024-07-09T09:41:03Z
dc.date.available2024-07-09T09:41:03Z
dc.date.issued2024-01-23
dc.identifier.citationJ Exp Clin Cancer Res. 2024 Jan 23;43(1):27.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/20318
dc.description.abstractBACKGROUND Peritoneal metastasis, which accounts for 85% of all epithelial ovarian carcinoma (EOC) metastases, is a multistep process that requires the establishment of adhesive interactions between cancer cells and the peritoneal membrane. Interrelations between EOC and the mesothelial stroma are critical to facilitate the metastatic process. No data is available so far on the impact of histone acetylation/deacetylation, a potentially relevant mechanism governing EOC metastasis, on mesothelial cells (MCs)-mediated adhesion. METHODS Static adhesion and peritoneal clearance experiments were performed pretreating mesenchymal-like MCs and platinum-sensitive/resistant EOC cell lines with MS-275-a Histone deacetylase (HDAC)1-3 pharmacological inhibitor currently used in combination trials. Results were acquired by confocal microscopy and were analyzed with an automated Opera software. The role of HDAC1/2 was validated by genetic silencing. The role of α4-, α5-α1 Integrins and Fibronectin-1 was validated using specific monoclonal antibodies. Quantitative proteomic analysis was performed on primary MCs pretreated with MS-275. Decellularized matrices were generated from either MS-275-exposed or untreated cells to study Fibronectin-1 extracellular secretion. The effect of MS-275 on β1 integrin activity was assessed using specific monoclonal antibodies. The role of Talin-1 in MCs/EOC adhesion was analyzed by genetic silencing. Talin-1 ectopic expression was validated as a rescue tool from MS-275-induced phenotype. The in vivo effect of MS-275-induced MC remodeling was validated in a mouse model of peritoneal EOC dissemination. RESULTS Treatment of MCs with non-cytotoxic concentrations of MS-275 caused a consistent reduction of EOC adhesion. Proteomic analysis revealed several pathways altered upon MC treatment with MS-275, including ECM deposition/remodeling, adhesion receptors and actin cytoskeleton regulators. HDAC1/2 inhibition hampered actin cytoskeleton polymerization by downregulating actin regulators including Talin-1, impairing β1 integrin activation, and leading to abnormal extracellular secretion and distribution of Fibronectin-1. Talin-1 ectopic expression rescued EOC adhesion to MS-275-treated MCs. In an experimental mouse model of metastatic EOC, MS-275 limited tumor invasion, Fibronectin-1 secretion and the sub-mesothelial accumulation of MC-derived carcinoma-associated fibroblasts. CONCLUSION Our study unveils a direct impact of HDAC-1/2 in the regulation of MC/EOC adhesion and highlights the regulation of MC plasticity by epigenetic inhibition as a potential target for therapeutic intervention in EOC peritoneal metastasis.es_ES
dc.description.sponsorshipThis research was funded by: AIRC (Associazione Italiana per la Ricerca sul Cancro) (IG26172) and Ateneo Sapienza Project 2020 (RG120172B8E53D03) to S.V; by FISR2019_00374 MeDyCa to AM; by FSE REACT-EU within the program PON “Research and Innovation” 2014–2020, Action IV.6 “Contratti di ricerca su tematiche Green” to CZ; by SEED PNR 2021 to C.B.; by AIRC IG26290, by Sapienza University of Rome (RG11916B6A9C42C7) to M. Tr and by Ministry for Health of Italy (Ricerca Corrente), by AIRC (IG21372 to LR), by PRIN 2022 PNRR (P2022XZKBM) fnanced by the European Union - NextGenerationEU», to RS. This work was also supported by grants (PID2019-110132RB-I00/AEI/https:// doi.org/10.13039/501100011033 and PID2022-142796OB-I00/AEI/https:// doi.org/10.13039/501100011033)) from the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICIN/FEDER) to ML-C and by a grant PID2021-123199OB-I00 from the Spanish Ministry of Science and Innovation/Fondo Europeo de Desarrollo Regional (MICIN/FEDER) to CC. MAdP is recipient/co-recipient of funding from the Spanish Ministry of Sci‑ ence and Innovation (MCIN) (refs. SAF2017–83130-R cofunded by “ERDF A way of making Europe”, PID2020-118658RB-I00, PDC2021–121572-100 cofunded by “European Union NextGeneration EU/PRTR”), Asociación Española Contra el Cáncer foundation (AECC; PROYE20089DELP); La Marató TV3 foundation (201936–30-31), Obra social La Caixa (AtheroConvergence, HR20–00075) and Comunidad Autónoma de Madrid/FEDER (Tec4Bio consortium, ref. S2018/ NMT¬4443). MS-A is recipient of a Ramón y Cajal research contract from MCIN (RYC2020–029690-I) and research grant PID2021-128106NA-I00, both from Spanish MCIN. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovación (MCIN) and the Pro CNIC Foundation), and is a Severo Ochoa Center of Excellence (grant CEX2020–001041-S funded by MICIN/ AEI/https://doi.org/10.13039/501100011033).es_ES
dc.language.isoenges_ES
dc.publisherBioMed Central (BMC) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subject.meshBenzamides es_ES
dc.subject.meshCarcinoma, Ovarian Epithelial es_ES
dc.subject.meshHistone Deacetylase 1 es_ES
dc.subject.meshOvarian Neoplasms es_ES
dc.subject.meshPeritoneal Neoplasms es_ES
dc.subject.meshHistone Deacetylase 2 es_ES
dc.subject.meshCell Adhesion es_ES
dc.subject.meshAnimals es_ES
dc.subject.meshFemale es_ES
dc.subject.meshHumans es_ES
dc.subject.meshMice es_ES
dc.subject.meshActin Cytoskeleton es_ES
dc.subject.meshAntibodies, Monoclonal es_ES
dc.subject.meshEpithelium es_ES
dc.subject.meshExtracellular Matrix Proteins es_ES
dc.subject.meshFibronectins es_ES
dc.subject.meshIntegrin alpha5 es_ES
dc.subject.meshIntegrin beta1 es_ES
dc.subject.meshProteomics es_ES
dc.subject.meshPyridines es_ES
dc.subject.meshTalin es_ES
dc.titleHDAC1/2 control mesothelium/ovarian cancer adhesive interactions impacting on Talin-1-α5β1-integrin-mediated actin cytoskeleton and extracellular matrix protein remodeling.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID38254102es_ES
dc.format.volume43es_ES
dc.format.number1es_ES
dc.format.page27es_ES
dc.identifier.doi10.1186/s13046-023-02930-8es_ES
dc.contributor.funderUnión Europea. Comisión Europea. NextGenerationEU es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España) es_ES
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) es_ES
dc.contributor.funderAsociación Española Contra el Cáncer es_ES
dc.contributor.funderFundación La Marató TV3 es_ES
dc.contributor.funderComunidad de Madrid (España) es_ES
dc.contributor.funderMinisterio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1756-9966es_ES
dc.relation.publisherversion10.1186/s13046-023-02930-8es_ES
dc.identifier.journalJournal of experimental & clinical cancer research : CRes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Mecanoadaptación y Biología de Caveolases_ES
dc.repisalud.institucionCNICes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2019-110132RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2022-142796OB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2021-123199OB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/SAF2017–83130-Res_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2020-118658RB-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PDC2021–121572-100es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PROYE20089DELPes_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/201936–30-31es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/HR20–00075es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/S2018/NMT/4443es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/RYC2020–029690-Ies_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/PID2021-128106NA-I00es_ES
dc.relation.projectFECYTinfo:eu-repo/grantAgreement/ES/10.13039/501100011033/CEX2020–001041-Ses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional